Supplementary Table S2. Association between baseline characteristics and presence of *BRCA* reversion mutations in pretreatment circulating cell-free DNA (cfDNA)

	Patients with *BRCA* reversion mutations detected in pretreatment cfDNA (*n* = 8)	Patients without *BRCA* reversion mutations detected in pretreatment cfDNA (*n* = 89)	Fisher's exact *P* value
Histological classification, *n* (%)			
Serous	7 (87.5)	86 (96.6)	0.2953
Endometrioid	1 (12.5)	1 (1.1)	
Mixed	0 (0)	2 (2.2)	
BRCA mutation type, *n* (%)			
Germline	5 (62.5)	62 (69.7)	0.6996
Somatic	3 (37.5)	27 (30.3)	
BRCA gene with deleterious mutation, *n* (%)			
BRCA1	4 (50.0)	56 (62.9)	0.4757
BRCA2	4 (50.0)	33 (37.1)	
Number of prior chemotherapy regimens, *n* (%)			
1	0 (0)	8 (9.0)	0.3915
2	0 (0)	10 (11.2)	
3	3 (37.5)	44 (49.4)	
4	5 (62.5)	27 (30.3)	
Platinum response to last therapy, *n* (%)			
Sensitive	1 (12.5)	47 (52.8)	0.0488
Resistant	5 (62.5)	33 (37.1)	
Refractory	2 (25.0)	9 (10.1)	